Search
Influenza B virus B/Phuket/3073/2013 live (attenuated) antigen
go.drugbank.com/drugs/DB11036ApprovedInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. … A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses.
Cucurbita pepo subsp. ovifera whole
go.drugbank.com/drugs/DB15592ApprovedCucurbita pepo subsp. ovifera whole allergenic extract is used in allergenic testing.
Salanersen
go.drugbank.com/drugs/DB18418InvestigationalBIIB115 is an investigational antisense oligonucleotide in development for spinal muscular atrophy.
Oxfenicine
go.drugbank.com/drugs/DB04291ExperimentalOxfenicine in an inhibitor of myocardial metabolism of nonesterified fatty acids (NEFA).
Synonyms: L-4-hydroxyphenylglycine, L-2-(p-hydroxyphenyl)glycineDimetacrine
go.drugbank.com/drugs/DB08996ApprovedWithdrawnDimetacrine is a tricyclic antidepressant (TCA) with imipramine-like effects used in Europe for the treatment of depression. Dimetacrine is no longer used in Japan.
Synonyms: 3-(9,9-dimethylacridin-10-yl)-N,N-dimethyl-propan-1-amineGTI 2040
go.drugbank.com/drugs/DB05801InvestigationalGTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.
Hypothiocyanite ion
go.drugbank.com/drugs/DB15309InvestigationalHypothiocyanite ion is under investigation in clinical trial NCT02598999 (Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients).
Trelagliptin
go.drugbank.com/drugs/DB15323InvestigationalTrelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").
LSZ-102
go.drugbank.com/drugs/DB15362InvestigationalLSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).